Jeff Szekeres
Director/Board Member at Andelyn Biosciences
Profile
Jeff Szekeres is currently a Director at Andelyn Biosciences, Inc. He was previously a Director at Invitrogen Corp.
and a Director at Eurofins Genomics Blue Heron LLC.
Jeff Szekeres active positions
Companies | Position | Start |
---|---|---|
Andelyn Biosciences
Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Director/Board Member | - |
Former positions of Jeff Szekeres
Companies | Position | End |
---|---|---|
Invitrogen Corp.
Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Invitrogen develops, manufactures and markets research tools in kit form and provides other research products and services to corporate, academic and government entities. These research kits simplify and improve gene cloning, gene expression and gene analysis techniques. | Director/Board Member | - |
Eurofins Genomics Blue Heron LLC
Eurofins Genomics Blue Heron LLC Miscellaneous Commercial ServicesCommercial Services Eurofins Genomics Blue Heron LLC engages in the development of accurate gene synthesis platform for the production of genes and gene variants for use in expression analysis. Its services include GeneMaker technology, vector synthesis & custom cloning, plasmid preparation, and variant library. The company was founded by John Mulligan in 1999 and is headquartered in Bothell, WA. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Eurofins Genomics Blue Heron LLC
Eurofins Genomics Blue Heron LLC Miscellaneous Commercial ServicesCommercial Services Eurofins Genomics Blue Heron LLC engages in the development of accurate gene synthesis platform for the production of genes and gene variants for use in expression analysis. Its services include GeneMaker technology, vector synthesis & custom cloning, plasmid preparation, and variant library. The company was founded by John Mulligan in 1999 and is headquartered in Bothell, WA. | Commercial Services |
Invitrogen Corp.
Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Invitrogen develops, manufactures and markets research tools in kit form and provides other research products and services to corporate, academic and government entities. These research kits simplify and improve gene cloning, gene expression and gene analysis techniques. | Electronic Technology |
Andelyn Biosciences
Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Health Technology |
- Stock Market
- Insiders
- Jeff Szekeres